Partnering
Early R&D collaboration
Serendip collaborates from the early stages with academic institutions, biotechnology, and biopharmaceutical companies to explore the feasibility of new application ideas.
For instance, Serendip seeks partners to test:
- Encapsulating mRNA and small molecules
- Directly conjugating adjuvants to the particles
- Testing a prophylactic vaccine on an animal model
- Evaluating different antigens for cancer vaccine applications
The best way to proceed is to contact us and discover if the modularity of our particle can benefit your application.
Investment partnership
Serendip collaborates with private, corporate and institutional investors focused on developing technology platforms.
Currently, Serendip has a clear path to reach clinical phases and is seeking investment partners to bring this project to fruition.
The platform effect enables a variety of risk-reducing investment strategies.
Co-development and licensing partnership
After conducting a feasibility study in collaboration, Serendip plans to partner with biotechnology and biopharmaceutical companies to co-develop products and license the technology platform or the final product. Early collaboration is highly beneficial.
The strength of our particle lies in its ability to adapt to the mode of action, the target, and the active substance that the partner needs to vectorize.
Serendip already has the capability to license:
- The nanoparticle
- The nanoparticle adapted into an efficient immunization system
Through a partnership agreement, Serendip can offer an option to license the first vaccine candidate within the next three years.
Early
R&D collaboration
IBMC
Serendip is collaborating with IBMC on in-vitro and in-vivo testing of products manufactured in plants. Proof-of-concept (PoC) results for therapeutic vaccines targeting dendritic cells are the fruit of this collaboration.
Support &
funding
Academic laboratories
Start-up incubator and support
Funding
Training
